Combined modality therapy for non-small cell lung carcinoma.

Mitchell Machtay, Eli Glatstein

Research output: Contribution to journalReview articlepeer-review

4 Scopus citations

Abstract

Combined modality therapy is frequently used to treat non-small cell lung carcinoma (NSCLC). Surgical resection is the mainstay of treatment for Stages I and II NSCLC. Little evidence supports the use of adjuvant therapy In patients with Stage I NSCLC. Adjuvant radiotherapy to the chest after resection for Stage II and IIIA NSCLC remains controversial but may be appropriate for many patients with resected Stage IIIA disease or inadequately pathologically staged II disease. For Stage IIIA NSCLC, surgery appears suboptimal, though no other single modality appears superior. Recent studies of neoadjuvant therapy for Stage IIIA NSCLC yielded promising results. The standard of care for Stage III unresectable NSCLC and strategies to improve local-regional control in Stage III NSCLC are discussed, as are the importance of toxicity protection with chemoradiation and the potential utility of prophylactic cranial irradiation for preventing brain relapse. Targeted therapies appear promising, and expedited evaluation in Stage III NSCLC is warranted.

Original languageEnglish (US)
Pages (from-to)S55-67
JournalCancer journal (Sudbury, Mass.)
Volume8 Suppl 1
StatePublished - 2002

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Combined modality therapy for non-small cell lung carcinoma.'. Together they form a unique fingerprint.

Cite this